dalteparin has been researched along with Burns in 13 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Burns: Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The evidence suggests a need to evaluate different dosing protocols among burns patients in order to improve AFXa levels, with the aim of decreasing incidence of VTE in high-risk patients." | 1.62 | Venous thromboembolism in burns patients: Are we underestimating the risk and underdosing our prophylaxis? ( Bortz, H; Cleland, H; Harms, KA; Lo, C; Lu, P; Paul, E, 2021) |
| " Our objective was to evaluate the efficacy of enoxaparin dosed 40 mg twice daily in achieving prophylactic plasma anti-Xa levels in obese burn patients." | 1.62 | Single-center Experience with Venous Thromboembolism Prophylaxis for Obese Burn Patients. ( Jones, S; King, B; McKinzie, BP; Nizamani, R; Williams, FN, 2021) |
| " While 30-mg twice-daily enoxaparin is accepted as the standard prophylactic dose, recent evidence in injured patients suggests this dosing strategy may result in sub-optimal pharmacologic DVT prophylaxis." | 1.51 | Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients. ( Berndtson, AE; Box, K; Costantini, TW; Cronin, BJ; Godat, LN; Kolan, S; Lee, JG; Pham, A, 2019) |
| " We describe the first case report, to our knowledge, of a severely burned patient who, despite prophylactic dosing of enoxaparin 30 mg subcutaneously twice daily, developed an acute DVT that required high-dose enoxaparin (100 mg [1." | 1.48 | Increased Enoxaparin Dosing Requirements for Treatment of Deep Vein Thrombosis in a Severely Burned Patient: Case Report and Literature Review. ( Haan, BJ; Mangan, KC; Yost, RJ, 2018) |
| "The high prevalence of deep vein thrombosis (DVT) reported in prospective studies and the unreliability of clinical diagnosis mandates prospective screening for DVT in burn patients." | 1.43 | An analysis of deep vein thrombosis in burn patients (Part 1): Comparison of D-dimer and Doppler ultrasound as screening tools. ( Ahuja, RB; Bansal, P; Pradhan, GS; Subberwal, M, 2016) |
| "Frequent occurrence of low antifactor Xa levels observed in this study demonstrated the inadequacy of standard dosing of enoxaparin for VTE prophylaxis in many patients with acute burns." | 1.37 | Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients. ( Cochran, A; Faraklas, I; Lin, H; Saffle, J, 2011) |
| " The low antifactor Xa levels that were observed suggest that a reduced dose-response relationship may exist between subcutaneously administered enoxaparin and antifactor Xa activity in patients with severe burn injuries." | 1.32 | Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism. ( Angood, PB; Gandhi, PJ; Smith, BS; Yogaratnam, D, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Payne, A | 1 |
| Richardson, P | 1 |
| Muthayya, P | 1 |
| Lu, P | 1 |
| Harms, KA | 1 |
| Paul, E | 1 |
| Bortz, H | 1 |
| Lo, C | 1 |
| Cleland, H | 1 |
| McKinzie, BP | 1 |
| Nizamani, R | 1 |
| Jones, S | 1 |
| King, B | 1 |
| Williams, FN | 1 |
| Vicci, H | 1 |
| Eblen-Zajjur, A | 1 |
| López, M | 1 |
| Crespo, G | 1 |
| Navarro, M | 1 |
| Yost, RJ | 1 |
| Haan, BJ | 1 |
| Mangan, KC | 1 |
| Cronin, BJ | 1 |
| Godat, LN | 1 |
| Berndtson, AE | 1 |
| Pham, A | 1 |
| Kolan, S | 1 |
| Box, K | 1 |
| Lee, JG | 1 |
| Costantini, TW | 1 |
| Sebastian, R | 1 |
| Ghanem, O | 1 |
| DiRoma, F | 1 |
| Milner, SM | 1 |
| Price, LA | 1 |
| Mojsiewicz-Pieńkowska, K | 1 |
| Jamrógiewicz, M | 1 |
| Żebrowska, M | 1 |
| Mikolaszek, B | 1 |
| Sznitowska, M | 1 |
| Ahuja, RB | 2 |
| Bansal, P | 2 |
| Pradhan, GS | 2 |
| Subberwal, M | 2 |
| Lin, H | 1 |
| Faraklas, I | 1 |
| Saffle, J | 1 |
| Cochran, A | 1 |
| Yogaratnam, D | 1 |
| Smith, BS | 1 |
| Angood, PB | 1 |
| Gandhi, PJ | 1 |
| Ferguson, RE | 1 |
| Critchfield, A | 1 |
| Leclaire, A | 1 |
| Ajkay, N | 1 |
| Vasconez, HC | 1 |
1 review available for dalteparin and Burns
| Article | Year |
|---|---|
Pulmonary embolism in burns, is there an evidence based prophylactic recommendation? Case report and review of literature.
Topics: Adult; Anticoagulants; Burns; Enoxaparin; Evidence-Based Medicine; Female; Humans; Obesity; Pulmonar | 2015 |
2 trials available for dalteparin and Burns
| Article | Year |
|---|---|
Double layer adhesive silicone dressing as a potential dermal drug delivery film in scar treatment.
Topics: Adhesives; Administration, Cutaneous; Adult; Bandages; Burns; Cicatrix; Drug Delivery Systems; Enoxa | 2015 |
An analysis of deep vein thrombosis in burn patients (part II): A randomized and controlled study of thrombo-prophylaxis with low molecular weight heparin.
Topics: Adolescent; Adult; Body Surface Area; Burns; Disease Management; Enoxaparin; Epistaxis; Female; Fibr | 2016 |
10 other studies available for dalteparin and Burns
| Article | Year |
|---|---|
VTE prophylaxis and anti-factor Xa measurement in major burns: A survey of UK practice.
Topics: Anticoagulants; Burns; Enoxaparin; Humans; United Kingdom; Venous Thromboembolism | 2023 |
Venous thromboembolism in burns patients: Are we underestimating the risk and underdosing our prophylaxis?
Topics: Adult; Aged; Anticoagulants; Australia; Burns; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Inc | 2021 |
Single-center Experience with Venous Thromboembolism Prophylaxis for Obese Burn Patients.
Topics: Adult; Aged; Anticoagulants; Burns; Drug Administration Schedule; Enoxaparin; Female; Humans; Male; | 2021 |
Enoxaparin pretreatment effect on local and systemic inflammation biomarkers in the animal burn model.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Antithrombin III; Biomarkers; Burns; C-Reactive P | 2019 |
Increased Enoxaparin Dosing Requirements for Treatment of Deep Vein Thrombosis in a Severely Burned Patient: Case Report and Literature Review.
Topics: Adult; Anticoagulants; Burns; Enoxaparin; Factor Xa; Humans; Male; Monitoring, Physiologic; Venous T | 2018 |
Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Body Mass Index; Body Weight; Burns; Chemoprev | 2019 |
An analysis of deep vein thrombosis in burn patients (Part 1): Comparison of D-dimer and Doppler ultrasound as screening tools.
Topics: Adolescent; Adult; Body Surface Area; Burns; Disease Management; Enoxaparin; Female; Fibrin Fibrinog | 2016 |
Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Burn Units; Burns; Cohort | 2011 |
Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism.
Topics: Adult; Antithrombin III; Burns; Enoxaparin; Female; Humans; Male; Venous Thrombosis | 2004 |
Current practice of thromboprophylaxis in the burn population: a survey study of 84 US burn centers.
Topics: Anticoagulants; Burn Units; Burns; Dalteparin; Enoxaparin; Health Surveys; Heparin; Humans; Risk Fac | 2005 |